Viatris (2)

Executive Summary

Viatris is a global healthcare company formed in 2020 through the merger of Mylan and Upjohn, with a mission to provide broad access to high-quality medicines across generics, complex generics, biosimilars, and branded products. The company’s scale and diversified portfolio position it as a key player in the pharmaceutical value chain, though its reliance on legacy products and generic pricing pressures pose challenges. Viatris has been actively streamlining its portfolio through divestitures and focusing on high-growth areas such as biosimilars and complex generics, which could drive margin expansion. With a valuation of approximately $15.5 billion and a strong commercial product base, the company is poised for steady, albeit moderate, growth as it navigates patent expirations and competitive dynamics.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of Biosimilar to Stelara (ustekinumab)75% success
• Q4 2026Launch of Complex Generic in Respiratory Therapy Area60% success
• Q2 2026Divestiture of Non-Core Assets to Streamline Portfolio80% success